Bethlehem, PA – Arria NLG, a global leader in natural language generation, today announced that Glemser Technologies will augment its Life Sciences Practice with a natural language generation (NLG) solution powered by Arria technology.

“Choosing to work with Arria NLG to provide our clients with a way to automate the writing of medical reports was a natural choice,” says Ray Glemser, CEO. “NLG allows companies to save significant time and money while increasing scalability and efficiency. Arria’s break-through technology will transform the way our customers bring life-saving drugs to market.”

Glemser understands the unique challenges pharma companies face. Bringing a drug to market can be a difficult, costly, and drawn-out process. Pharma companies consistently have to report to regulators, governments, and consumers on drug efficacy and safety. They are constantly under pressure to deliver increased transparency, accountability, and innovation in their drug-development process while staying on budget. Through strategic application of technology, Glemser is committed to helping their clients modernize their drug-development processes.

By automating some of the most time-consuming and expensive manual reporting needed to ensure compliance and safety, firms can reap cost savings, and they can free their medical writers from the tedious work that is most prone to human error. Faster reporting means they can present findings to regulatory authorities more quickly. Improved accuracy, early on in the reporting process, means better compliance and faster regulatory approval ultimately extending patent life.

Gartner predicts that by 2022, 25% of enterprises will use some form of NLG technology to transform their businesses. Natural language generation (NLG), a form of artificial intelligence, transforms the drug development process by automating clinical safety report generation. This streamlining reduces operating costs for pharma companies and allows their writers to focus on higher-value tasks. As a result, companies can bring life-saving drugs to market faster.

For over 30 years, Glemser has served life science clients by assuring product quality, improving regulatory compliance and gaining operational efficiencies that reduce costs. They develop industry-leading IT solutions and services that are essential for pharma companies throughout North America, Europe, and Asia — helping them solve their most pressing challenges in quality, compliance, and efficiency.

“We are in a crucial moment, given today’s world events, that the improvement of efficiency, scale, and speed to market of our pharmaceutical companies is more important than ever,” said Sharon Daniels, CEO of Arria. “Our team here at Arria is committed to sustainability and social responsibility. Offering our technology in this partnership with Glemser is a path to expedite decision making and time to insights for those companies working to create treatments and vaccines for critical ailments.”

It is Arria’s hope that through this partnership, Glemser customers may be able to bring life-saving treatment to patients faster.

Glemser serves life science clients by ensuring product quality, improving regulatory compliance, and gaining operational efficiencies that reduce costs. They develop industry-leading IT solutions and services that are essential for life science clients throughout North America, Europe, and Asia to solve their most pressing challenges in quality, compliance, and efficiency. Dedication to client success is of the upmost importance to them, as evidenced though their quality and proven methods for over 30 years. Their talented global professionals and approach to quality result in client engagements that are on time, on budget, and on benefit.

Arria is the global leader in Natural Language Generation (NLG)—which transforms structured data into natural language. Through algorithms and modeling, Arria software replicates the human process of expertly analyzing and communicating data insights—dynamically turning data into written or spoken narrative—at machine speed and massive scale.

Arria has the greatest concentration of NLG expertise in the world and has a growing patent portfolio of 28 core NLG patents. Arria’s rapidly growing group of major international enterprise clients—including banking, financial services, insurance, pharmaceutical, consumer product goods, news and media—are now deploying NLG-driven automated reporting within their global organizations using Arria’s NLG Studio Platform. Arria’s industry partners include: Accenture, BNY Mellon, Cognizant, Deloitte, Genpact, Glemser, IBM and many others. Additional information is available at